Get the Stockscreener App
33.50
0.99%
0.33
After Hours:
33.50
Tg Therapeutics Inc stock is traded at $33.50, with a volume of 1.45M.
It is up +0.99% in the last 24 hours and up +19.64% over the past month.
See More
Previous Close:
$33.17
Open:
$33
24h Volume:
1.45M
Relative Volume:
0.51
Market Cap:
$4.54B
Revenue:
$264.79M
Net Income/Loss:
$-14.36M
P/E Ratio:
-304.55
EPS:
-0.11
Net Cash Flow:
$-28.11M
1W Performance:
+0.42%
1M Performance:
+19.64%
6M Performance:
+62.78%
1Y Performance:
+118.24%
1-Day Range:
$32.61
$33.84
1-Week Range:
$30.59
$33.88
52-Week Range:
$12.84
$36.84
Tg Therapeutics Inc Stock (TGTX) Company Profile
Name
Tg Therapeutics Inc
Sector
Industry
Phone
(212) 554-4484
Address
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Compare TGTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TGTX
Tg Therapeutics Inc
|
33.50 | 4.54B | 264.79M | -14.36M | -28.11M | -0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-29-24 | Initiated | TD Cowen | Buy |
| Aug-02-23 | Upgrade | Goldman | Sell → Neutral |
| Jun-26-23 | Resumed | Jefferies | Buy |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Nov-15-21 | Downgrade | Goldman | Neutral → Sell |
| Apr-20-21 | Initiated | Goldman | Neutral |
| Apr-19-21 | Reiterated | H.C. Wainwright | Buy |
| Sep-01-20 | Initiated | JP Morgan | Overweight |
| Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Initiated | Evercore ISI | Outperform |
| Jan-17-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Feb-06-19 | Resumed | Jefferies | Buy |
| Sep-25-18 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-09-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-01-17 | Resumed | B. Riley FBR, Inc. | Buy |
| Nov-14-17 | Resumed | H.C. Wainwright | Buy |
| Apr-25-17 | Initiated | Jefferies | Buy |
| Mar-06-17 | Reiterated | FBR & Co. | Outperform |
| Oct-06-16 | Resumed | Brean Capital | Buy |
| May-27-16 | Initiated | SunTrust | Buy |
| Dec-01-15 | Initiated | FBR Capital | Outperform |
| Sep-09-15 | Initiated | Raymond James | Strong Buy |
| Aug-12-15 | Resumed | H.C. Wainwright | Buy |
| Jun-19-15 | Reiterated | Brean Capital | Buy |
| Dec-11-14 | Reiterated | ROTH Capital | Buy |
| Dec-10-14 | Reiterated | ROTH Capital | Buy |
View All
Tg Therapeutics Inc Stock (TGTX) Latest News
TG Therapeutics (NASDAQ:TGTX) Rating Lowered to "Sell" at StockNews.com - MarketBeat
Precision Wealth Strategies LLC Buys Shares of 17,608 TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat
Symphony Financial Ltd. Co. Takes Position in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat
Nisa Investment Advisors LLC Buys 2,803 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World
Trading (TGTX) With Integrated Risk Controls - Stock Traders Daily
All You Need to Know About TG Therapeutics (TGTX) Rating Upgrade to Buy - MSN
TG Therapeutics (NASDAQ:TGTX) Stock Price Up 6.8%Here's What Happened - MarketBeat
Why TGTX Stock Is Rallying Today - MSN
TG Therapeutics: Entering 2025 With Increased Investor Expectations (NASDAQ:TGTX) - Seeking Alpha
Cantor Fitzgerald Weighs in on TG Therapeutics FY2025 Earnings - Defense World
Assenagon Asset Management S.A. Decreases Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat
TG Therapeutics: 2025 Revenues Will Smash Expectations (NASDAQ:TGTX) - Seeking Alpha
12 Hot Stocks to Buy According to Analysts - Insider Monkey
Here’s Why Analysts Are Bullish on TG Therapeutics, Inc. (TGTX) - Insider Monkey
TG Therapeutics (TGTX) Moves 7.5% Higher: Will This Strength Last? - MSN
(TGTX) Trading Signals - Stock Traders Daily
Brookstone Capital Management Acquires 624 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World
FY2024 EPS Forecast for TG Therapeutics Increased by Analyst - Defense World
Is TG Therapeutics Inc. (TGTX) Among Tuesday’s Top Gainers? - MSN
TG Therapeutics FY2024 EPS Forecast Raised by HC Wainwright - MarketBeat
TG Therapeutics Provides Preliminary Fourth Quarter and Full-Year Financial Results in SEC Filing - Defense World
TG Therapeutics: Cash Positive But Playing Defense (Rating Downgrade) (NASDAQ:TGTX) - Seeking Alpha
TG Therapeutics FY2025 EPS Forecast Raised by HC Wainwright - MarketBeat
TG Therapeutics' (TGTX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
TGTX Announces 2024 Preliminary Results, 2025 Goals, Shares Rise - MSN
Exploring Three High Growth Tech Stocks In The United States - Yahoo Finance
Have Insiders Sold TG Therapeutics Shares Recently? - Simply Wall St
Expert Outlook: TG Therapeutics Through The Eyes Of 5 Analysts - Benzinga
TG Therapeutics stock rises on strong Q4 and full-year revenue - Investing.com Australia
10 Firms Post Impressive Gains on Tuesday - Insider Monkey
TG Therapeutics Reports Strong Revenue and Future Goals - TipRanks
TG Therapeutics Shares Climb 7% as Sales Grow for Multiple Sclerosis Drug - MarketWatch
TG Therapeutics Provides Preliminary Fourth Quarter and - GlobeNewswire
TG Therapeutics (NASDAQ:TGTX) Shares Gap UpHere's Why - MarketBeat
TG Therapeutics projects $540 million in 2025 revenue By Investing.com - Investing.com Nigeria
What's Going On With TG Therapeutics Stock Tuesday? - Benzinga
TG Therapeutics says 2024 Briumvi sales topped expectations - MSN
TG Therapeutics stock rises on strong Q4 and full-year revenue By Investing.com - Investing.com South Africa
TG Therapeutics stock gains on Briumvi sales (TGTX:NASDAQ) - Seeking Alpha
TG Therapeutics projects $540 million in 2025 revenue - Investing.com
TG Therapeutics' BRIUMVI Hits $310M Revenue in 2024, Projects 75% Growth for 2025 - StockTitan
Brokerages Set TG Therapeutics, Inc. (NASDAQ:TGTX) PT at $40.67 - MarketBeat
TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
TG Therapeutics: Subcutaneous Briumvi Data A Key Near-Term Catalyst (NASDAQ:TGTX) - Seeking Alpha
Tg Therapeutics Inc Stock (TGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):